Abstract
Unfolding and aggregation of monoclonal antibodies (mAbs) can cause pathologic immunogenicity and significant loss of material during production and processing. Destabilizing conditions were used to accelerate degradation and probe environment effects relevant to pharmaceutical formulations. Currently approved mAb therapeutics harness the immunological capability of the major IgG class of immunoglobulin in blood serum; the IgG1 subclass was selected for our studies. High hydrostatic pressure (HP) was used for in-situ measurements of subzero °C temperatures in the absence of ice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
